Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Disease Progression × TPI-287 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 2 Glioblastoma 2 Recurrence 1 Melanoma 1 Medulloblastoma 1 Gliosarcoma 1 Disease Progression 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1

Interventions

fludarabine 1 famitinib 1 encorafenib 1 camrelizumab 1 TPI-287 1 Sodium Selenite 1 Nivolumab 1 Ifosfamide 1 Cyclophosphamide 1 Clinical Trials, Phase II as Topic 1 Clinical Trials, Phase I as Topic 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01340729 2013-04-05

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn

Melanoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡